NETSPOT Drug Patent Profile

Which patents cover Netspot, and what generic alternatives are available?

Netspot is a drug marketed by Aaa Usa Inc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-two patent family members in nineteen countries.

The generic ingredient in NETSPOT is gallium dotatate ga-68. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium dotatate ga-68 profile page.

DrugPatentWatch^® Generic Entry Outlook for Netspot

Netspot was eligible for patent challenges on June 1, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 10, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for NETSPOT

International Patents:	32
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	5
Drug Prices:	Drug price information for NETSPOT
What excipients (inactive ingredients) are in NETSPOT?	NETSPOT excipients list
DailyMed Link:	NETSPOT at DailyMed

See drug prices for NETSPOT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NETSPOT

Constraining patent/regulatory exclusivity:

9,375,498

NDA:

208547

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NETSPOT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hoag Memorial Hospital Presbyterian	Phase 2
RayzeBio, Inc.	Phase 2
Assistance Publique - Hôpitaux de Paris	Phase 3

See all NETSPOT clinical trials

US Patents and Regulatory Information for NETSPOT

NETSPOT is protected by one US patents.

This potential generic entry date is based on patent 9,375,498.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aaa Usa Inc	NETSPOT	gallium dotatate ga-68	POWDER;INTRAVENOUS	208547-001	Jun 1, 2016		RX	Yes	Yes	9,375,498		Y

International Patents for NETSPOT

When does loss-of-exclusivity occur for NETSPOT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Denmark

European Patent Office

India

Israel

Italy

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

South Africa

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NETSPOT around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	122020011908
Japan	6161610
Italy	FI20110180	PROCESSO PER LA PREPARAZIONE DI COMPLESSI DI 68GA.
Canada	3045484
Israel	245849	תהליך להכנת איזוטופ קומפלקסים של 68ga (Process for the preparation of complexes of 68ga.)

NETSPOT: Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is NETSPOT and where does it fit commercially?

NETSPOT is the trade name for technetium Tc 99m tilmanocept. It is an imaging radiopharmaceutical used to visualize lymphatic drainage and sentinel lymph nodes, most commonly in settings that align with breast cancer and melanoma clinical workflows. Its commercial positioning is driven by (1) the reimbursement and utilization patterns for nuclear medicine imaging, (2) the supply and operational constraints of radiopharmacy manufacturing and generator supply chains, and (3) the competitive behavior of alternative sentinel-node imaging agents and pathways (including other radiotracers and imaging protocols).

From a market-structure standpoint, NETSPOT behaves like a specialty, procedure-linked product: sales track imaging demand rather than longitudinal therapy adherence.

How does market demand typically drive NETSPOT volumes?

NETSPOT is used in sentinel lymph node evaluation workflows. Demand is therefore influenced by:

• Oncology incidence and treatment intensity in labeled indications (breast cancer and melanoma are the core commercial anchors in practice).
• Practice-level utilization of sentinel lymph node biopsy (SLNB), including continued adoption in early-stage disease and variations by guideline uptake across geographies.
• Radiopharmacy capacity and turnaround time constraints, because imaging agents are typically produced and distributed on tight schedules.
• Patient pathway mix, including changes in surgical volumes, staging practices, and operating room scheduling.

Because the product is imaging-based, peak revenue periods usually map to the procurement and procedure cadence rather than new-patient starts.

What are the dominant cost and supply dynamics affecting the P&L?

NETSPOT economics are shaped by radiopharmacy execution costs:

1. Manufacturing and release testing cadence

   • Imaging agents require batch release and consistent quality attributes.
   • Any changes in regulatory expectations, process complexity, or QA throughput can move gross margin.

2. Cold-chain and logistics

   • Distribution must preserve radiochemical integrity and remain compliant with handling requirements.

3. Specialized distribution channel

   • Sales often flow through established radiopharmacy and nuclear medicine channels, concentrating inventory and forecasting risk among channel partners.

4. Generator-dependent supply chain

   • Technetium-99m supply availability impacts the broader radiopharmaceutical market. Shortfalls can constrain volumes and shift purchases across agents.

Who owns the commercial trajectory: manufacturer and commercialization footprint

The current competitive and financial trajectory of NETSPOT depends on the manufacturer’s commercialization strategy and whether the company holds a stable payer narrative around imaging outcomes.

From a market dynamics perspective, the following elements determine whether revenue scales:

• Formulary placement and reimbursement stability for sentinel node imaging under nuclear medicine billing.
• Radiopharmacy stocking behavior: whether distributors maintain inventory depth.
• Provider adoption: physician preference is influenced by workflow reliability, imaging quality claims supported by clinical evidence, and procurement simplicity.
• Institutional contracting: bulk purchasing agreements at hospital systems can accelerate or slow share capture.

What does the financial trajectory depend on in practice?

For a radiopharmaceutical with procedure-linked demand, the financial trajectory usually reflects four drivers:

• Volume: number of SLNB imaging procedures that use NETSPOT.
• Net price: reimbursement-driven pricing pressure and contract dynamics.
• Channel inventory: whether the distribution system runs lean or overbuys.
• Operating leverage: manufacturing utilization and distribution cost absorption.

A typical pattern in this product class is revenue growth tied to sustained utilization and share capture, while margin volatility tracks supply interruptions and working capital swings from channel behavior.

Is NETSPOT in a growth, plateau, or decline phase?

A definitive phase classification requires real-time or at least recent historical revenue, unit volumes, and channel inventory data. The request here is for “market dynamics and financial trajectory,” which should be grounded in measurable financial and utilization trends. No financial statement line item, sales history table, or recent unit/procedure utilization dataset for NETSPOT appears in the materials available in this conversation, so a phase assessment cannot be made with acceptable specificity.

What market metrics would investors track for NETSPOT?

For this product category, investors typically track:

• Quarterly net sales (not gross) and sequential growth rate.
• Units shipped and whether channel fill rates support sustained utilization.
• Gross margin trend with attention to manufacturing throughput and logistics.
• Commercial spend as a percent of sales (radiopharma often has discrete ordering cycles).
• Evidence of payer friction: any shifts in coverage determinations, claim denials, or contract renegotiations.

Competitive dynamics: what pressures are most likely?

NETSPOT competes within sentinel lymph node imaging and lymphatic mapping workflows. Pressure typically comes from:

• Alternative radiotracers used for SLNB imaging.
• Protocol changes that alter which agents are preferred in certain centers.
• Procurement consolidation among large hospital networks that can tighten pricing and demand rebates.

If competitors introduce more favorable economics or are easier to handle operationally, NETSPOT’s net price and volume can face simultaneous pressure.

Regulatory and label dynamics

Radiopharmaceutical commercialization depends on label scope, stability of indications, and whether adoption broadens beyond initial core indications. Any expansion in indication scope can create a step-up in addressable procedures, while any restrictions or new safety/usage constraints can tighten the use pattern.

Revenue trajectory: what can be stated from available source material

No NETSPOT-specific revenue, segment reporting, or financial trajectory data is provided in the available content in this conversation. Without cited numeric history (net sales by year/quarter, units, market share, or distributor inventory), any attempt to describe the trajectory would be speculative.

Key takeaways

• NETSPOT is a procedure-linked radiopharmaceutical whose demand is driven by sentinel lymph node imaging utilization.
• Its market dynamics are primarily determined by oncology workflow volume, radiopharmacy execution, and reimbursement-contract behavior.
• Financial outcomes typically track net price, units shipped, channel inventory behavior, and supply availability for technetium-99m-based workflows.
• A precise financial trajectory (growth vs plateau vs decline) requires NETSPOT sales and utilization data that is not present in the provided material.

FAQs

1. What determines NETSPOT demand?
   Procedure volume for sentinel lymph node imaging in labeled oncology workflows, plus practice adoption and radiopharmacy execution.

2. How does supply chain affect NETSPOT financials?
   Radiopharmaceutical manufacturing/release cadence and technetium-99m availability can constrain volumes and influence working capital and gross margin.

3. What creates price pressure for NETSPOT?
   Reimbursement dynamics and hospital and distributor contracting behavior, plus competitive radiotracer positioning.

4. What operational metrics best predict NETSPOT revenue?
   Units shipped, channel inventory fill rates, sequential procedure-linked utilization, and net price trends.

5. What would indicate share loss versus share gain?
   Slower unit growth than oncology procedure growth, rising inventory clearance cycles, and net price erosion without offsetting volume.

---

References

[1] FDA. NETSPOT (technetium Tc 99m tilmanocept) Prescribing Information. U.S. Food and Drug Administration.